China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has published clinical data for its COVID-19 vaccine candidate SCB-2019 (CpG 1018/Alum) as a third shot. The double-blind, randomized, controlled study demonstrated significant increases in neutralizing antibodies against Omicron variants BA.2 and BA.1.
Clinical Study Results
The study enrolled 3,755 subjects in Brazil, the Philippines, and Colombia, assessing the immunogenicity and safety of SCB-2019 as both primary immunization and a booster. Results showed that baseline seronegative subjects who received the homologous booster experienced a 19-fold increase in neutralizing antibodies against Omicron BA.2 and a 12-fold increase against BA.1.
Market Filings and Commercialization
Clover Bio is on track to complete market filings with the National Medical Products Administration (NMPA), European Medicine Agency (EMA), and World Health Organization (WHO) later this year. The company is also preparing for the commercialization of the product, positioning it as a vital tool in the ongoing global response to the COVID-19 pandemic.-Fineline Info & Tech
